These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39177931)

  • 21. Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia.
    Goncalves MD; Farooki A
    Integr Cancer Ther; 2022; 21():15347354211073163. PubMed ID: 35075945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
    Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
    Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
    Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
    Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
    Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
    Wang DG; Barrios DM; Blinder VS; Bromberg JF; Drullinsky PR; Funt SA; Jhaveri KL; Lake DE; Lyons T; Modi S; Razavi P; Sidel M; Traina TA; Vahdat LT; Lacouture ME
    Breast Cancer Res Treat; 2020 Aug; 183(1):227-237. PubMed ID: 32613539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
    Shen S; Chen Y; Carpio A; Chang C; Iyengar NM
    Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
    Burnette SE; Poehlein E; Lee HJ; Force J; Westbrook K; Moore HN
    Breast Cancer Res Treat; 2023 Jan; 197(2):369-376. PubMed ID: 36409396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
    Han S; Hagan DL; Taylor JR; Xin L; Meng W; Biller SA; Wetterau JR; Washburn WN; Whaley JM
    Diabetes; 2008 Jun; 57(6):1723-9. PubMed ID: 18356408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
    Mayer IA; Prat A; Egle D; Blau S; Fidalgo JAP; Gnant M; Fasching PA; Colleoni M; Wolff AC; Winer EP; Singer CF; Hurvitz S; Estévez LG; van Dam PA; Kümmel S; Mundhenke C; Holmes F; Babbar N; Charbonnier L; Diaz-Padilla I; Vogl FD; Sellami D; Arteaga CL
    Clin Cancer Res; 2019 May; 25(10):2975-2987. PubMed ID: 30723140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
    Tankova T; Senkus E; Beloyartseva M; Borštnar S; Catrinoiu D; Frolova M; Hegmane A; Janež A; Krnić M; Lengyel Z; Marcou Y; Mazilu L; Mrinakova B; Percik R; Petrakova K; Rubovszky G; Tokar M; Vrdoljak E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multidisciplinary approach to optimizing care of patients treated with alpelisib.
    Rugo HS; Lacouture ME; Goncalves MD; Masharani U; Aapro MS; O'Shaughnessy JA
    Breast; 2022 Feb; 61():156-167. PubMed ID: 35016012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
    Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
    Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
    J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
    Sharma P; Abramson VG; O'Dea A; Nye L; Mayer I; Pathak HB; Hoffmann M; Stecklein SR; Elia M; Lewis S; Scott J; De Jong JA; Wang YY; Yoder R; Schwensen K; Finke K; Heldstab J; LaFaver S; Williamson SK; Phadnis MA; Reed GA; Kimler BF; Khan QJ; Godwin AK
    Clin Cancer Res; 2021 Jul; 27(14):3896-3904. PubMed ID: 33602685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
    Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
    Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpelisib to treat breast cancer.
    Copur MS
    Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
    Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
    Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
    Liu D; Weintraub MA; Garcia C; Goncalves MD; Sisk AE; Casas A; Harding JJ; Harnicar S; Drilon A; Jhaveri K; Flory JH
    Cancer Med; 2022 Apr; 11(8):1796-1804. PubMed ID: 35212193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.